Resident’s Forum
RF-Conjuntivitis Associated With Dupilumab in Atopic Dermatitis
FR-Conjuntivitis asociada a dupilumab en dermatitis atópica
M. Munera-Campos
, J.M. Carrascosa
Autor para correspondencia
Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain
Leído
4540
Vecesse ha leído el artículo
1705
Total PDF
2835
Total HTML
Compartir estadísticas
array:25 [ "pii" => "S1578219020303103" "issn" => "15782190" "doi" => "10.1016/j.adengl.2019.07.026" "estado" => "S300" "fechaPublicacion" => "2020-12-01" "aid" => "2422" "copyright" => "AEDV" "copyrightAnyo" => "2020" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2020;111:872-3" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:20 [ "pii" => "S0001731020302441" "issn" => "00017310" "doi" => "10.1016/j.ad.2019.07.008" "estado" => "S300" "fechaPublicacion" => "2020-12-01" "aid" => "2422" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2020;111:872-3" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Foro de Residentes</span>" "titulo" => "FR-Conjuntivitis asociada a dupilumab en dermatitis atópica" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "872" "paginaFinal" => "873" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "RF-Conjuntivitis Associated With Dupilumab in Atopic Dermatitis" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Munera-Campos, J.M. Carrascosa" "autores" => array:2 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "Munera-Campos" ] 1 => array:2 [ "nombre" => "J.M." "apellidos" => "Carrascosa" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219020303103" "doi" => "10.1016/j.adengl.2019.07.026" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219020303103?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731020302441?idApp=UINPBA000044" "url" => "/00017310/0000011100000010/v1_202012050701/S0001731020302441/v1_202012050701/es/main.assets" ] ] "itemSiguiente" => array:20 [ "pii" => "S1578219020303292" "issn" => "15782190" "doi" => "10.1016/j.adengl.2020.10.029" "estado" => "S300" "fechaPublicacion" => "2020-12-01" "aid" => "2429" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2020;111:874" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Images in Dermatology</span>" "titulo" => "Differences in Ultrasound Scanners’ Detection of Metastasis in Melanoma" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "874" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Diferencias en equipos de ecografía para la detección de metástasis de melanoma" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 537 "Ancho" => 1305 "Tamanyo" => 94413 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P. Giavedoni, D. Morgado-Carrasco, J. Puig, S. Malvehy" "autores" => array:4 [ 0 => array:2 [ "nombre" => "P." "apellidos" => "Giavedoni" ] 1 => array:2 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" ] 2 => array:2 [ "nombre" => "J." "apellidos" => "Puig" ] 3 => array:2 [ "nombre" => "S." "apellidos" => "Malvehy" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731020302714" "doi" => "10.1016/j.ad.2018.08.021" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731020302714?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219020303292?idApp=UINPBA000044" "url" => "/15782190/0000011100000010/v1_202012160744/S1578219020303292/v1_202012160744/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S1578219020303085" "issn" => "15782190" "doi" => "10.1016/j.adengl.2019.07.025" "estado" => "S300" "fechaPublicacion" => "2020-12-01" "aid" => "2439" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2020;111:870-1" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Resident's Forum</span>" "titulo" => "RF-Sentinel Lymph Node Biopsy in Head and Neck Melanoma" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "870" "paginaFinal" => "871" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "FR-Biopsia Selectiva de Ganglio Centinela en Melanoma de Cabeza y Cuello" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "T. Montero-Vilchez, A. Martinez-Lopez, L. Salvador-Rodriguez, S. Arias-Santiago" "autores" => array:4 [ 0 => array:2 [ "nombre" => "T." "apellidos" => "Montero-Vilchez" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Martinez-Lopez" ] 2 => array:2 [ "nombre" => "L." "apellidos" => "Salvador-Rodriguez" ] 3 => array:2 [ "nombre" => "S." "apellidos" => "Arias-Santiago" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731020302842" "doi" => "10.1016/j.ad.2019.07.010" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731020302842?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219020303085?idApp=UINPBA000044" "url" => "/15782190/0000011100000010/v1_202012160744/S1578219020303085/v1_202012160744/en/main.assets" ] "en" => array:17 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Resident’s Forum</span>" "titulo" => "RF-Conjuntivitis Associated With Dupilumab in Atopic Dermatitis" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "872" "paginaFinal" => "873" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "M. Munera-Campos, J.M. Carrascosa" "autores" => array:2 [ 0 => array:4 [ "nombre" => "M." "apellidos" => "Munera-Campos" "email" => array:1 [ 0 => "monicamunera@hotmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "J.M." "apellidos" => "Carrascosa" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "FR-Conjuntivitis asociada a dupilumab en dermatitis atópica" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Atopic dermatitis (AD) is the most frequent inflammatory dermatosis. Up to 20% of patients have moderate to severe disease. Of these, 20%–43% may experience ocular symptoms, including conjunctivitis, keratitis, and blepharitis.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Dupilumab is the first monoclonal antibody approved for the treatment of moderate to severe AD. It binds to the common alfa subunit of interleukins (IL) 4 and IL-13, leading to a reduction in Th2-mediated inflammation and an improvement in epidermal barrier function. Although it is expected that control of AD could also improve ocular manifestations, in clinical trials, IL-4/IL-13 blockade with dupilumab is associated with a greater frequency of ocular manifestations than observed in the control group, which received placebo (incidence of 5%–28%, according to dose, compared with 1%–8%, respectively).<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2–4</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Two basic clinical patterns of ocular involvement associated with the use of dupilumab have been reported:<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">•</span><p id="par0020" class="elsevierStylePara elsevierViewall">Nonspecific conjunctivitis, associated with dots on the cornea in the lower third and evaporative dry eye (lacrimal secretion is quantitatively normal but of a lower quality). This form can respond to measures to hydrate the ocular surface.</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">•</span><p id="par0025" class="elsevierStylePara elsevierViewall">Follicular conjunctivitis, more specific, generally bilateral and of a mild to moderate severity, associated with pruritus, burning sensation, and increased tear production. It is characteristic of limbal hyperemia and can be accompanied by blepharitis. This form is refractory to humectants and requires topical anti-inflammatory treatment.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p></li></ul></p><p id="par0030" class="elsevierStylePara elsevierViewall">The cause of ocular manifestations associated with dupilumab is unknown, although the mechanism could be inflammatory and specific to AD, given that administration in patients with asthma or nasal polyposis has not been associated with an increased risk of conjunctivitis. The risk factors for its development include severe AD, personal history of conjunctivitis, and low serum levels of dupilumab.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> It is postulated that inhibition of IL-4/IL-13 itself could increase the activity of OX40L—which participates in the development of atopic keratoconjunctivitis—and also reduce the number of intraepithelial goblet cells; this would explain the lower proportion of mucin observed, in turn impacting tear quality.<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5,6</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">For diagnosis of dupilumab-associated conjunctivitis, it is essential to obtain a detailed clinical history, and findings of the eye examination (exudate, pruritus, and concurrent symptoms) and slit lamp assessment, to be performed by ophthalmologists. Differential diagnosis with other forms of conjunctivitis is essential, particularly, infectious forms.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> The therapeutic recommendations are presented in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0040" class="elsevierStylePara elsevierViewall">Following approval of dupilumab in Europe, an increase in the number of patients with drug-related ocular manifestations could be expected. It would be desirable to raise awareness of this potential issue, and put in place measures for their prevention and management. Prior ophthalmological assessment is recommended before administration of the drug, along with active screening for this possible side effect, as well as the development of new therapeutic algorithms.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Conflicts ofinterest</span><p id="par0045" class="elsevierStylePara elsevierViewall">J.M. Carrascosa has received speaker and consultant fees from Sanofi and fees as an investigator in clinical trials from Sanofi, Lilly, Leo-Pharma, Pfizer, and Amgen. M. Munera-Campos has participated in and received fees as an investigator in clinical trials from Lilly, Leo-Pharma, and Pfizer.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:4 [ 0 => array:2 [ "identificador" => "xpalclavsec1310295" "titulo" => "Palabras clave" ] 1 => array:2 [ "identificador" => "xpalclavsec1310296" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "sec0005" "titulo" => "Conflicts ofinterest" ] 3 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2019-07-10" "fechaAceptado" => "2019-07-13" "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1310296" "palabras" => array:4 [ 0 => "Atopic dermatitis" 1 => "Dupilumab" 2 => "Conjuntivitis" 3 => "Tratamiento" ] ] ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Munera-Campos M, Carrascosa JM. FR-Conjuntivitis asociada a dupilumab en dermatitis atópica. Actas Dermosifiliogr. 2020;111:872–873.</p>" ] ] "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Agent \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Availability \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Benefits \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Adverse effects \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="4" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Hydration of the ocular surface</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " rowspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Application of bandages or warm towels (10 min, 1 or 2 times a day)</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Commercialized</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Improves function of the Meibomian glands \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Stabilization of the lacrimal film \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " rowspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Artificial tears (carmellose sodium 0.5%, trehalose 3%, and/or sodium hyaluronate 0.15%–4%)</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Commercialized</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rehydration of the ocular surface \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sensitization to preservatives</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">May resolve nonspecific forms of conjunctivitis, associated with evaporative dry eye \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="4" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Anti-inflammatory treatments</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " rowspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Fluorometholone 0.1%</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Commercialized</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lower risk of glaucoma or cataracts compared with other topical corticoids (minimal penetration of the ocular anterior chamber)</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sensitization to preservatives \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Care should be taken regarding the possibility of glaucoma and/or cataracts with chronic use (class adverse effect) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " rowspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Tacrolimus (concentrations of 0.03% and 0.1%)</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Commercialized \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Decrease in conjunctival inflammation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Compassionate use \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Magistral formulation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Does not increase the risk of glaucoma or cataracts \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ocular irritation \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " rowspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ciclosporin (concentrations of 0.05%–2%)</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Marketed at 0.1% (therapeutic indication in severe keratitis in adults with xerophthalmia) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Decrease in conjunctival inflammation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Compassionate use \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Magistral formulation at other concentrations \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Does not increase the risk of glaucoma or cataracts \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ocular irritation, local burning sensation, or pain on application \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2469261.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Therapeutic Recommendations for Management of Dupilumab-Associated Conjunctivitis.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:6 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atopic keratoconjunctivitis: a review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J.J. Chen" 1 => "D.S. Applebaum" 2 => "G.S. Sun" 3 => "S.C. Pflugfelder" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2013.10.036" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol." "fecha" => "2014" "volumen" => "70" "paginaInicial" => "569" "paginaFinal" => "575" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24342754" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Two phase 3 trials of dupilumab versus placebo in atopic dermatitis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E.L. Simpson" 1 => "T. Bieber" 2 => "E. Guttman-Yassky" 3 => "L.A. Beck" 4 => "A. Blauvelt" 5 => "M.J. Cork" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1610020" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med." "fecha" => "2016" "volumen" => "375" "paginaInicial" => "2335" "paginaFinal" => "2348" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27690741" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. De Bruin-Weller" 1 => "D. Thaci" 2 => "C.H. Smith" 3 => "K. Reich" 4 => "M.J. Cork" 5 => "A. Radin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.16156" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol." "fecha" => "2018" "volumen" => "178" "paginaInicial" => "1083" "paginaFinal" => "1101" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29193016" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Blauvelt" 1 => "M. de Bruin-Weller" 2 => "M. Gooderham" 3 => "J.C. Cather" 4 => "J. Weisman" 5 => "D. Pariser" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Lancet (London, England)." "fecha" => "2017" "volumen" => "389" "paginaInicial" => "2287" "paginaFinal" => "2303" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ocular surface diseases induced by dupilumab in severe atopic dermatitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A. Maudinet" 1 => "S. Law-Koune" 2 => "C. Duretz" 3 => "A. Lasek" 4 => "P. Modiano" 5 => "T.H.C. Tran" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Ophthalmol Ther." "fecha" => "2019" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Management of dupilumab-associated conjunctivitis in atopic dermatitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "N. Aszodi" 1 => "S. Thurau" 2 => "M. Seegraber" 3 => "M. de Bruin-Weller" 4 => "A. Wollenberg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/ddg.13809_g" "Revista" => array:6 [ "tituloSerie" => "J Dtsch Dermatol Ges." "fecha" => "2019" "volumen" => "17" "paginaInicial" => "488" "paginaFinal" => "491" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31115977" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000011100000010/v1_202012160744/S1578219020303103/v1_202012160744/en/main.assets" "Apartado" => array:4 [ "identificador" => "34945" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Resident's Forum" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000011100000010/v1_202012160744/S1578219020303103/v1_202012160744/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219020303103?idApp=UINPBA000044" ]
| año/Mes | Html | Total | |
|---|---|---|---|
| 2024 Noviembre | 4 | 4 | 8 |
| 2024 Octubre | 94 | 39 | 133 |
| 2024 Septiembre | 85 | 23 | 108 |
| 2024 Agosto | 93 | 56 | 149 |
| 2024 Julio | 77 | 33 | 110 |
| 2024 Junio | 73 | 32 | 105 |
| 2024 Mayo | 61 | 28 | 89 |
| 2024 Abril | 71 | 24 | 95 |
| 2024 Marzo | 80 | 29 | 109 |
| 2024 Febrero | 60 | 33 | 93 |
| 2024 Enero | 53 | 33 | 86 |
| 2023 Diciembre | 51 | 15 | 66 |
| 2023 Noviembre | 69 | 32 | 101 |
| 2023 Octubre | 68 | 25 | 93 |
| 2023 Septiembre | 56 | 23 | 79 |
| 2023 Agosto | 56 | 20 | 76 |
| 2023 Julio | 68 | 31 | 99 |
| 2023 Junio | 42 | 22 | 64 |
| 2023 Mayo | 56 | 26 | 82 |
| 2023 Abril | 40 | 14 | 54 |
| 2023 Marzo | 54 | 23 | 77 |
| 2023 Febrero | 35 | 17 | 52 |
| 2023 Enero | 26 | 32 | 58 |
| 2022 Diciembre | 52 | 47 | 99 |
| 2022 Noviembre | 34 | 19 | 53 |
| 2022 Octubre | 29 | 27 | 56 |
| 2022 Septiembre | 17 | 38 | 55 |
| 2022 Agosto | 33 | 42 | 75 |
| 2022 Julio | 29 | 41 | 70 |
| 2022 Junio | 23 | 22 | 45 |
| 2022 Mayo | 34 | 59 | 93 |
| 2022 Abril | 53 | 28 | 81 |
| 2022 Marzo | 58 | 62 | 120 |
| 2022 Febrero | 46 | 38 | 84 |
| 2022 Enero | 50 | 42 | 92 |
| 2021 Diciembre | 48 | 42 | 90 |
| 2021 Noviembre | 49 | 48 | 97 |
| 2021 Octubre | 57 | 60 | 117 |
| 2021 Septiembre | 47 | 55 | 102 |
| 2021 Agosto | 32 | 30 | 62 |
| 2021 Julio | 38 | 37 | 75 |
| 2021 Junio | 43 | 50 | 93 |
| 2021 Mayo | 151 | 57 | 208 |
| 2021 Abril | 207 | 90 | 297 |
| 2021 Marzo | 80 | 52 | 132 |
| 2021 Febrero | 54 | 27 | 81 |
| 2021 Enero | 72 | 37 | 109 |
| 2020 Diciembre | 81 | 27 | 108 |
| 2020 Noviembre | 29 | 13 | 42 |
| 2020 Octubre | 17 | 1 | 18 |
Mostrar todo
